BACKGROUND: We compared a conventional empirically derived regimen with a simplified regimen for parenteral artesunate in severe malaria. METHODS: This was a randomized, double-blind, placebo-controlled comparison to assess the noninferiority of a simplified 3-dose regimen (given at 0, 24, and 48 hours) compared with the conventional 5-dose regimen of intravenous artesunate (given at 0, 12, 24, 48, and 72 hours) in African children with Plasmodium falciparum malaria with a prespecified delta of 0.2. The total dose of artesunate in each group was 12 mg/kg. The primary end point was the proportion of children clearing ≥ 99% of their admission parasitemia at 24 hours. Safety data, secondary efficacy end points, and pharmacokinetics were also analyzed. RESULTS: In 171 children (per protocol), 78% of the recipients (95% confidence interval [CI], 69%-87%) in the 3-dose group achieved ≥ 99% parasite clearance 24 hours after the start of treatment, compared with 85% (95% CI, 77%-93%) of those receiving the conventional regimen (treatment difference, -7.2%; 95% CI, -18.9% to 4.4%). Dihydroartemisinin was cleared slightly more slowly in those children receiving the higher 3-dose regimen (7.4 vs 8.8 L/h for a 13-kg child; P 5 .008). CONCLUSIONS: Pharmacodynamic analysis suggests that 3 doses of artesunate were not inferior to 5 doses for the treatment of severe malaria in children. CLINICAL TRIALS REGISTRATION: NCT00522132.
RCT Entities:
BACKGROUND: We compared a conventional empirically derived regimen with a simplified regimen for parenteral artesunate in severe malaria. METHODS: This was a randomized, double-blind, placebo-controlled comparison to assess the noninferiority of a simplified 3-dose regimen (given at 0, 24, and 48 hours) compared with the conventional 5-dose regimen of intravenous artesunate (given at 0, 12, 24, 48, and 72 hours) in African children with Plasmodium falciparum malaria with a prespecified delta of 0.2. The total dose of artesunate in each group was 12 mg/kg. The primary end point was the proportion of children clearing ≥ 99% of their admission parasitemia at 24 hours. Safety data, secondary efficacy end points, and pharmacokinetics were also analyzed. RESULTS: In 171 children (per protocol), 78% of the recipients (95% confidence interval [CI], 69%-87%) in the 3-dose group achieved ≥ 99% parasite clearance 24 hours after the start of treatment, compared with 85% (95% CI, 77%-93%) of those receiving the conventional regimen (treatment difference, -7.2%; 95% CI, -18.9% to 4.4%). Dihydroartemisinin was cleared slightly more slowly in those children receiving the higher 3-dose regimen (7.4 vs 8.8 L/h for a 13-kg child; P 5 .008). CONCLUSIONS: Pharmacodynamic analysis suggests that 3 doses of artesunate were not inferior to 5 doses for the treatment of severe malaria in children. CLINICAL TRIALS REGISTRATION: NCT00522132.
Authors: Aminatou Kone; Jianbing Mu; Hamma Maiga; Abdoul H Beavogui; Omar Yattara; Issaka Sagara; Mamadou M Tekete; Oumar B Traore; Antoine Dara; Souleymane Dama; Nouhoum Diallo; Aly Kodio; Aliou Traoré; Anders Björkman; Jose P Gil; Ogobara K Doumbo; Thomas E Wellems; Abdoulaye A Djimde Journal: J Infect Dis Date: 2012-11-16 Impact factor: 5.226
Authors: Patrick S Twomey; Bryan L Smith; Cathy McDermott; Anne Novitt-Moreno; William McCarthy; S Patrick Kachur; Paul M Arguin Journal: Ann Intern Med Date: 2015-10-06 Impact factor: 25.391
Authors: Arjen M Dondorp; Richard J Maude; Ilse C E Hendriksen; Nicholas P Day; Nicholas J White Journal: J Infect Dis Date: 2012-06-25 Impact factor: 5.226
Authors: S G Zaloumis; J Tarning; S Krishna; R N Price; N J White; T M E Davis; J M McCaw; P Olliaro; R J Maude; P Kremsner; A Dondorp; M Gomes; K Barnes; J A Simpson Journal: CPT Pharmacometrics Syst Pharmacol Date: 2014-11-05
Authors: Peter G Kremsner; Akim A Adegnika; Aurore B Hounkpatin; Jeannot F Zinsou; Terrie E Taylor; Yamikani Chimalizeni; Alice Liomba; Maryvonne Kombila; Marielle K Bouyou-Akotet; Denise P Mawili Mboumba; Tsiri Agbenyega; Daniel Ansong; Justice Sylverken; Bernhards R Ogutu; Godfrey A Otieno; Anne Wangwe; Kalifa A Bojang; Uduak Okomo; Frank Sanya-Isijola; Charles R Newton; Patricia Njuguna; Michael Kazungu; Reinhold Kerb; Mirjam Geditz; Matthias Schwab; Thirumalaisamy P Velavan; Christian Nguetse; Carsten Köhler; Saadou Issifou; Stefanie Bolte; Thomas Engleitner; Benjamin Mordmüller; Sanjeev Krishna Journal: PLoS Med Date: 2016-01-12 Impact factor: 11.069
Authors: I C E Hendriksen; G Mtove; A Kent; S Gesase; H Reyburn; M M Lemnge; N Lindegardh; N P J Day; L von Seidlein; N J White; A M Dondorp; J Tarning Journal: Clin Pharmacol Ther Date: 2013-02-08 Impact factor: 6.875
Authors: Michael T Hawkes; Sarah Forgie; Jason Brophy; Maryanne Crockett Journal: Can J Infect Dis Med Microbiol Date: 2015 Sep-Oct Impact factor: 2.471